Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Kyoto, 606-8507, Japan.
Shiga Medical Center Research Institute, 5-4-30 Moriyama, Moriyama, Shiga, 524-8523, Japan.
Hear Res. 2018 Oct;368:92-108. doi: 10.1016/j.heares.2018.07.004. Epub 2018 Jul 6.
The hybrid or electric-acoustic stimulation cochlear implant is indicated in patients with a residual hearing at low frequencies. It provides electric and acoustic stimulation for compensating for high- and low-frequency sounds, respectively. However, the implantation procedure damages the cochlea, resulting in loss of the residual-hearing and diminished effects of the acoustic-hearing in several patients. To prevent hearing loss after implantation, corticosteroids have been used clinically although their effects are limited. As an alternative to corticosteroids, insulin-like growth factor 1 (IGF1) has shown potent effects in various types of cochlear injury. In this study, the effects of IGF1 on hearing preservation were examined after cochlear implantation to a normal-hearing guinea pig model. The electrode was inserted in an atraumatic way through the round window membrane of guinea pigs with the application of a gelatin-sponge soaked with IGF1 or saline. The auditory brainstem response (ABR) was recorded pre-operatively, immediately after cochlear implantation, and 7, 14, 28, and 56 days after electrode insertion. In comparison to the control group, the IGF1-treated group showed better hearing preservation at low frequencies, 7 days after surgery. IGF1 application was effective at low frequencies (2 and 4 kHz) throughout the period of examination. Histological studies revealed that outer hair cell numbers, in the IGF1-treated group, were maintained in the cochlear region responsible for low-frequency hearing (upper midbasal turn) and that there was less fibrous tissue formation around the electrode. Both the outer hair cell counts and the extent of fibrosis significantly correlated with the ABR threshold shifts at low frequencies. These results indicate that IGF1 might attenuate loss of low-frequency hearing after cochlear implantation, suggesting its possible clinical use in soft surgeries involving cochlear implants with electric-acoustic stimulation for hearing preservation.
混合或电-声刺激人工耳蜗植入物适用于低频残余听力的患者。它提供电刺激和声学刺激,分别补偿高低频声音。然而,植入手术会损伤耳蜗,导致一些患者残余听力丧失和声学听力效果减弱。为了防止植入后听力损失,临床上已经使用了皮质类固醇,尽管它们的效果有限。作为皮质类固醇的替代品,胰岛素样生长因子 1(IGF1)在各种类型的耳蜗损伤中显示出强大的效果。在这项研究中,研究了 IGF1 在正常听力豚鼠模型的耳蜗植入后对听力保护的影响。通过将电极以无创伤的方式插入豚鼠的圆窗膜,同时应用含有 IGF1 或生理盐水的明胶海绵。在手术前、耳蜗植入后立即以及电极插入后 7、14、28 和 56 天记录听觉脑干反应(ABR)。与对照组相比,IGF1 处理组在手术后 7 天表现出更好的低频听力保护。IGF1 应用在整个检查期间对低频(2 和 4 kHz)都有效。组织学研究表明,在 IGF1 处理组中,外毛细胞数量在负责低频听力的耳蜗区域(中基底转上部)得到维持,并且电极周围形成的纤维组织较少。外毛细胞数量和纤维化程度均与低频 ABR 阈值变化显著相关。这些结果表明,IGF1 可能减轻耳蜗植入后低频听力损失,提示其在软手术中可能用于电-声刺激人工耳蜗植入物的听力保护。